TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05461521

Intervention type: OTHER
Intervention: Family members of patients admitted to the ICU
Description: At inclusion:~* Collection of demographic data, Anxiety-Depression Scale (HADS), Insomnia Severity Index (ISI), Resilience Insomnia Severity Index (ISI), Resilience Scale (CD RISC 10), Peritraumatic Dissociation Peritraumatic Dissociation Experience Scale (PDEQ) and MEDEC questionnaire.~* Venous blood sampling at 350 relatives~* Upon discharge of the patient (alive or deceased): Resuscitation questionnaire, HADS, ISI and PDEQ.~  3 months after discharge: Demographic questionnaire, Post Traumatic Stress Disorder questionnaire (PCL-5), THS Past Trauma Experience Questionnaire, HADS experiences, HADS, ISI, CD RISC 10, MEDEC and Who- assist questionnaire (Question 2) on the use of psychoactive substances.~  6 months after patient discharge: PCL-5, HADS, ISI, CD RISC 10, MEDEC, Who-assist (Question 2) and Prolonged Grief disorder (PG-13) questionnaire on bereavement if patient died in the ICU.

Intervention type: OTHER
Intervention: Health care professionals
Description: All professionals in all categories and in all participating departments will be asked to complete questionnaires to assess the level of conflict, work stress and burn out in the units : Masclach Burnout Inventory (MBI), Job Content Questionnaire (JCQ), Ethical Decision-Making Climate Questionnaire (EDMCQ), Professional Quality Of Life scale (ProQOL), Connor-Davidson Resilience scale (CD-RISC 10), Cultural Awareness Scale (CAS).

Intervention type: OTHER
Intervention: Patients
Description: Inclusion (at D3 after admission to the ICU): collection of demographic data Discharge from the ICU: characteristics of the stay and outcome (alive/deceased)
Study: NCT04915768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505 TF chTrimer
Description: Combined with adjuvants 3M-052-AF and Alum. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505 TF chTrimer
Description: Combined with adjuvants 3M-052-AF and Alum. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505 TF chTrimer
Description: Combined with adjuvants 3M-052-AF and Alum. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505 TF chTrimer
Description: Combined with adjuvants 3M-052-AF and Alum. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-05-AF
Description: Combined with CH505 TF chTrimer and Alum adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-05-AF
Description: Combined with CH505 TF chTrimer and Alum adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-05-AF
Description: Combined with CH505 TF chTrimer and Alum adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-05-AF
Description: Combined with CH505 TF chTrimer and Alum adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide suspension
Description: Combined with CH505 TF chTrimer and 3M-052-AF adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide suspension
Description: Combined with CH505 TF chTrimer and 3M-052-AF adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle
Study: NCT06162715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Tirzepatide will be initiated 12 months after patients undergo Roux-en-Y Gastric Bypass. Patients will be started on the lowest dose of 2.5 mg and the dose increased every 6 weeks following an adaptive maximum dose titration protocol. Patients will then complete a final 4 weeks of the study drug.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care post-gastric bypass
Description: Patients randomized to the control arm will receive the standard of care for weight maintenance after gastric bypass including dietary guidance provided by the Vanderbilt Surgical Weight Loss handbook. This includes recommendations for 64 oz of fluids per day, ≥60 grams of protein/day, and daily bariatric multivitamins. Patients will continue to have access to dedicated bariatric dietitians, advanced practice providers, and surgeons on an ad hoc basis per patients' request.
Study: NCT04860414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: QPC Cognitive complaint questionnaire, CDR functional autonomy scales and IADL 4 items, MMSE cognitive scores, Dubois 5-word test, clock test, BREF, Isaacs test, BARD naming battery and MADRS depression scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: QPC Cognitive complaint questionnaire, CDR functional autonomy scales and IADL 4 items, MMSE cognitive scores, Dubois 5-word test, clock test, BREF, Isaacs test, BARD naming battery and MADRS depression scale
Study: NCT04764331

Intervention type: DEVICE
Group type: OTHER
Intervention: Revian Red All LED cap
Description: Cap that uses two wavelengths of light, 620 nm and 660 nm will be used once a day for 10 minutes.for treatment
Study: NCT06231693

Intervention type: DRUG
Intervention: Trastuzumab deruxtecan
Description: Patients with RE\<10% and HER2-Low breast cancer that have received Trastuzumab-deruxtecan in the metastatic setting
Study: NCT05929729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose
Description: Refer to arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovaFerrum
Description: Refer to arm/group descriptions
Study: NCT06564506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable acupuncture needles (0.30 × 75 mm)
Description: Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo needles (0.30 × 25 mm)
Description: Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Sham electroacupuncture will use blunt-tipped placebo needles without current output, which retract into their handles to simulate skin insertion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDZ-V electroacupuncture devices
Description: Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SDZ-V electroacupuncture devices
Description: Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.
Study: NCT05248230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-710
Description: 4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-710
Description: 4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-710
Description: 4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).
Study: NCT05987904

Intervention type: DEVICE
Intervention: LynxPatch
Description: Measurements with the LynxPatch device are conducted.

Intervention type: DEVICE
Intervention: LynxPatch
Description: Measurements with the LynxPatch device are conducted.
Study: NCT05821959

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AAVAnc80-hOTOF via Akouos Delivery Device
Description: AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time unilateral intracochlear administration using the Akouos Delivery Device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AAVAnc80-hOTOF via Akouos Delivery Device
Description: AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time unilateral intracochlear administration using the Akouos Delivery Device.
Study: NCT06200311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Description: Pulmonary vein isolation using pulsed field ablation (PFA), cryoballoon or radiofrequency ablation (RFA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological rhythm management
Description: 1st line: rate control, 2nd line: pharmacological rhythm management. 3rd line: AF ablation
Study: NCT04860414

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Assessment
Description: QPC Cognitive complaint questionnaire, CDR functional autonomy scales and IADL 4 items, MMSE cognitive scores, Dubois 5-word test, clock test, BREF, Isaacs test, BARD naming battery and MADRS depression scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subjective taste tests
Description: Scales of taste perceptive intensity, taste pleasure, hunger sensation (visual analogue scales from 0 to 10 cm) and food preferences on the one hand, and on the other hand, subjective tests of taste threshold determination by triangular tests of increasing sugar solution concentrations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subjective taste tests
Description: Scales of taste perceptive intensity, taste pleasure, hunger sensation (visual analogue scales from 0 to 10 cm) and food preferences on the one hand, and on the other hand, subjective tests of taste threshold determination by triangular tests of increasing sugar solution concentrations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subjective taste tests
Description: Scales of taste perceptive intensity, taste pleasure, hunger sensation (visual analogue scales from 0 to 10 cm) and food preferences on the one hand, and on the other hand, subjective tests of taste threshold determination by triangular tests of increasing sugar solution concentrations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Objective taste tests
Description: Recording of gustatory evoked potentials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Objective taste tests
Description: Recording of gustatory evoked potentials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Objective taste tests
Description: Recording of gustatory evoked potentials
Study: NCT06134921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (Active)
Description: Electrode placement based on the international 10 - 20 electroencephalography electrode system for the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.~In the Active-tDCS group, participants will receive real tDCS with intensity 2.0 mA for 30 minutes, with a 30-second ramp-up and ramp-down.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (active)
Description: Electrode placement based on the international 10 - 20 electroencephalography electrode system for the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial electrical stimulation (sham)
Description: Electrode placement based on the international 10 - 20 electroencephalography electrode system for applied the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.~In the Sham group, participants will receive sham stimulation with intensity 2.0 mA for 1 minute, with a 30-second ramp-up and ramp-down, and no stimulation until the end of 30 minutes of stimulation. Electrodes will remain for 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy program
Description: A conventional physical therapy program will be provided after 30 minutes of stimulation immediately. The program will be provided for both upper and lower limbs which consist of stretching exercise, active exercise, and functional exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy program
Description: A conventional physical therapy program will be provided after 30 minutes of stimulation immediately. The program will be provided for both upper and lower limbs which consist of stretching exercise, active exercise, and functional exercise.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional physical therapy program
Description: A conventional physical therapy program will be provided after 30 minutes of stimulation immediately. The program will be provided for both upper and lower limbs which consist of stretching exercise, active exercise, and functional exercise.
Study: NCT05138159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: Donafenib: 200mg po bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 capsule: According to the body surface area \<1.25m2 40mg/d, 1.25 \~ 1.5 m2 50 mg/d, \> 1.5m2 60mg/d po bid, taking 14 days, stopping for 7 days, 21 days for 1 cycle.
Study: NCT05299021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double-point SAPB
Description: A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 20-gauge needle was introduced craniocaudally using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration. And use the same method targeting the plane between the serratus anterior muscle and the third rib.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5 μ g/kg dexmedetomidine mixture will be injected into the two points with 15 ml separately.
Study: NCT04774419

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Description: To the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.
Study: NCT05299021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-point SAPB
Description: A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 20-gauge needle was introduced craniocaudally using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5μ g/kg dexmedetomidine mixture will be injected.
Study: NCT05075187

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic Screening
Description: Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.
Study: NCT05116449

Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaires
Description: Different quality of life questionnaires : FACT-B, EORTC QLQ-C30, QIC, BRIEF COPE, HADS, QSSS-C

Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaires
Description: Different quality of life questionnaires : FACT-B, EORTC QLQ-C30, QIC, BRIEF COPE, HADS, QSSS-C
Study: NCT05650723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib Pill
Description: 320 mg once per day by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib Pill
Description: 320 mg once per day by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Pill
Description: 400 mg once per day by mouth following the standard ramp-up schedule (20mg daily PO week 1, 50mg daily PO week 2, 100mg daily PO week 3, 200mg daily PO week 4, followed by 400mg PO daily week 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Pill
Description: 400 mg once per day by mouth following the standard ramp-up schedule (20mg daily PO week 1, 50mg daily PO week 2, 100mg daily PO week 3, 200mg daily PO week 4, followed by 400mg PO daily week 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab Injection
Description: 1000 mg IV given every 28 days
Study: NCT06082921

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beef Diet Intervention
Description: Participants will eat prepared meals including beef for 6 days. Participants will eat a habitual diet for 6 days prior to intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impossible Beef Diet Intervention
Description: Participants will eat prepared meals including impossible beef for one portion 6 days. Participants will eat a habitual diet for 6 days prior to intervention.
Study: NCT05453175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interrupting sitting with Physical activity
Description: Participants will engage in three minutes of walking, five sit to stands and five calf raises every thirty minutes
Study: NCT05768724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention diet
Description: The Resmena diet: It was characterized by a higher meal frequency, consisting of seven meals/d (including breakfast, lunch, dinner, and two snacks in the morning and two snacks in the afternoon), and by a different macronutrient distribution; 40% total energy value from CHO, 30% from proteins and 30% from lipids. This pattern tried to reinforce high n-3 polyunsaturated FA (n-3 PUFA) and high natural antioxidant food consumption and promoted low GL CHO intake as well as a high adherence to the Mediterranean diet. It also maintained a healthy FA profile and a cholesterol content of less than 300 mg/day.~* Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control diet
Description: Control diet: It was based on the American Heart Association (AHA) guidelines, including 3-5 meals per day, a macronutrient distribution of 55% total energy value from carbohydrates, 15% proteins, and 30% lipids, a healthy fatty acids (FA) profile and a cholesterol consumption lower than 300 mg/day.~- Daily meal plans were created according to the energy intake of the participants and sent to the participants via social media every week. Participants were asked to keep 3-day diet records to evaluate their compliance with the diet and were invited to the research center once a month to be checked
Study: NCT05461690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: 200mg once a day for patients with body weight \<77kg or baseline platelet count \<150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first.
Study: NCT05101135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT-001
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JT-001 Placebo
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT04062708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Preoperative Treatment:~* Non-squamous NSCLC: durvalumab 1125 mg, followed by pemetrexed 500 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~* Squamous NSCLC: durvalumab 1125 mg, followed by docetaxel 75 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Adjuvant Therapy:~• 1-6 weeks after completion of radiotherapy, durvalumab 1500 mg IV every 4 weeks will be administered for 13 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients will be re-evaluated following preoperative treatment to assess if patient is still medically fit to withstand surgery. Eligible patients will then undergo lobectomy, bilobectomy, sleeve lobectomy or other extended resection, or a pneumonectomy will be performed at the discretion of the attending thoracic surgeon.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 4-10 weeks after surgery, patients will receive 54 Gy of radiotherapy with single daily fractions.